An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Adafosbuvir (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 18 Dec 2017 Status changed from recruiting to completed.
- 20 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Nov 2017.
- 27 Sep 2016 Status changed from not yet recruiting to recruiting.